3 assets in Cervical Clear Cell Adenocarcinoma

Therapeutic assets addressing Cervical Clear Cell Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Cervical Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Lorigerlimab Cervical Clear Cell Adenocarcinoma	MacroGenics	P2	CCC (53)
Nivolumab Cervical Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)